As Lead of the Synthetic Biology Platform, Richie oversees all research conducted in this focus area including nucleic acid synthesis and sequencing, neurotechnology, gene therapy, aging reversal, gene editing, organism recoding, in situ omics, organ engineering, and projects involving the intersection of synthetic biology and synthetic chemistry. In addition to genetic engineering, his other interests include technologies that stimulate and record from the central nervous system. Prior to joining the Wyss Institute, Richie worked as Group Leader at the startup company Expansion Technologies, Inc. where he brought techniques and reagents for high resolution molecular mapping of tissues to market. Richie obtained his PhD in Organic Chemistry at the University of Illinois Urbana-Champaign where he synthesized complex, organic nanostructures for controlled release applications. As a postdoctoral fellow in the Department of Biomedical Engineering at Boston University and an affiliate of the MIT Media Lab, he developed surgical methods to deliver large molecules to the brain and created neurotransmitter-releasing DNA nanostructures.